about
sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse modelEffect of external ocular surgery and mode of post-operative care on plasminogen, plasmin, angiostatins and alpha(2)-macroglobulin in tears.Photorefractive keratectomy after intrastromal corneal ring segment explantation.Changes in higher order wavefront aberrations after contact lens corneal refractive therapy and LASIK surgery.Fluorophotometry as a diagnostic tool for the evaluation of dry eye diseaseEfficacy of topical cobalt chelate CTC-96 against adenovirus in a cell culture model and against adenovirus keratoconjunctivitis in a rabbit model.Conductive keratoplasty.The evaluation of corneal endothelial permeability in PERK study patients.Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivityThe Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical ResearchHLA-DR expression as a biomarker of inflammation for multicenter clinical trials of ocular surface diseaseComparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells.Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells.The core mechanism of dry eye disease is inflammation.The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee.Nutritional supplements for dry eye syndromeModulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution.Age-related cataract.Conductive keratoplasty and the coupling phenomenon.Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion.Corneal permeability changes in dry eye disease: an observational study.Contact lens-related Fusarium infection: case series experience in New York City and review of fungal keratitis.Red blood cell fatty acid analysis for determining compliance with omega3 supplements in dry eye disease trials.Microbial contamination of medications used to treat glaucomaNew insights into infectious keratitis.Emerging drugs for the treatment of dry eye disease.Clinical guidelines for management of dry eye associated with Sjögren disease.Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates.Omegas and Dry Eye: More Knowledge, More Questions.Retrospective report of antimicrobial susceptibility observed in bacterial pathogens isolated from ocular samples at Mount Sinai Hospital, 2010 to 2015.Precision and accuracy of TearLab osmometer in measuring osmolarity of salt solutions.Rapid diagnosis of ocular herpes simplex infections.Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.Nuclear translocation of NF-kappaB precedes apoptotic poly(ADP-ribose) polymerase cleavage during productive HSV-1 replication in corneal epithelial cells.Antibiotic Resistance Among Ocular Pathogens in the United States: Five-Year Results From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study.Efficacy of polyclonal antibodies for treatment of ocular herpes simplex infection.Corneal topography in corneal refractive therapy (CRT): a 1-month follow-up.Fluorophotometry to evaluate the corneal epithelium in eyes undergoing contact lens corneal reshaping to correct myopia.The response of Langerhans cells in the cornea to herpetic keratitis.Increasing prevalence of methicillin resistance in serious ocular infections caused by Staphylococcus aureus in the United States: 2000 to 2005.
P50
Q24635932-74C346FC-73B8-4EA4-A504-BDF2EC2E66EBQ30690374-5B5FD374-DAF6-42C3-A730-BE6F6DAA9026Q30829442-BE1A0777-C238-408F-85FE-DD098FCF3D88Q30983594-6F368904-D16F-4B5D-A52F-6206A0C9785DQ33244911-41694A8E-B34E-4ECE-B110-70F16DD400F1Q33245741-E6853E9E-AC49-4C8F-AE60-2926AA4FE337Q33287648-6E9ED9BE-8707-4482-A4DB-43B8F5461DA9Q33646292-A851C2C2-640A-46C6-98F6-4F8A0B589A24Q33648139-A3E04561-1E28-439A-A809-2E11AA8B42E9Q33756582-2E99CEF6-B1FF-4B17-BCF1-F3BEED2021E5Q33861286-D0960FC3-827D-4727-ACAD-EB59AD0C1EBEQ34218606-09CC52BC-975D-48D6-9ACA-252990AC04CAQ34309959-52A182F9-2C5A-4D1C-B7A6-32AB38BB30CDQ34510429-E6437DA5-315E-4DEE-93AE-92087C634ADBQ34769324-D27958A8-A5A8-4AF1-B4CC-F3AFF4400C2FQ35163639-F5F031A2-775F-4160-A469-3EE7FE10A91AQ35799409-FD7427AD-27AC-4251-8852-348778BC2277Q36039593-9B575D42-000C-4598-98DC-6597EE28B8D5Q36128111-6C6033FE-D287-43B1-8969-4D010295BCB8Q36640556-F472F323-7FDC-4717-A7FE-670F87CF1441Q36898549-8B62A34C-7975-439F-8541-8199FE5CBCB0Q36997658-E931D61A-6DA4-4B90-A7CE-039EC4F7F4ACQ37278493-2AADF54F-87CB-4606-A76E-7B63498CD0B7Q37311527-639A5814-1F77-4F41-8AD5-28486DF03397Q38065805-7FE7CD5C-B9CF-4388-A833-F827BCE1EBB4Q38102006-4970515B-890F-4637-85E8-E7F60ACA5893Q38424517-1B928745-AC9B-43B1-A7CA-8EA0E76690FAQ38427203-FF904F52-1D58-4F4E-8503-4C0BC7B560D1Q38545327-E8EB9B8A-B746-401C-84C1-BF965D6826BEQ39201681-8D3C593C-FD08-4641-AA02-FEE132D120EAQ39207493-5A7C14C4-0A8A-4DFA-9B8E-3854F48E626DQ39709366-1397C128-730D-4DBB-849D-CCD475E8919AQ39947594-D5485105-7A38-4734-8FB5-C963F53AE03BQ40061864-AA38FC66-1287-40C8-AD35-F43B5D860A07Q40937010-18A8477D-EC02-48B7-BB4D-63AF85367D10Q43645504-5839D418-177F-4EF7-81DC-7ABF00C0F053Q45119674-7DD92F46-9636-458C-89C2-2D84860FDD39Q46016789-5D96611C-9244-4667-A2F3-3768AC52B0F8Q46223344-63ECDCE9-8A24-4A33-9891-FBA6E58EB92EQ46601671-939F3805-D16C-4FF2-9A37-7AB51EE8B777
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Penny Asbell
@ast
Penny Asbell
@en
Penny Asbell
@es
Penny Asbell
@nl
Penny Asbell
@sl
type
label
Penny Asbell
@ast
Penny Asbell
@en
Penny Asbell
@es
Penny Asbell
@nl
Penny Asbell
@sl
prefLabel
Penny Asbell
@ast
Penny Asbell
@en
Penny Asbell
@es
Penny Asbell
@nl
Penny Asbell
@sl
P214
P244
P106
P1153
7005112598
P213
0000 0000 3470 8403
P214
P244
n2006181899
P31
P496
0000-0001-7583-7778
P735
P7859
lccn-n2006181899